Sugi Predict

Sugi Predict / Compounds / SCHEMBL21743256

SCHEMBL21743256

SCHEMBL21743256

CC(C)(C)OCCCN1CC[C@@H](F)C1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 12/20 0.43
▸ EHMT2 Q96KQ7 2/20 0.37
▸ HRH2 P25021 2/20 0.35
▸ HRH1 P35367 2/20 0.35
▸ MAOB P27338 2/20 0.34
▸ SLC6A4 P31645 3/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ PRKAB2 O43741 1/20 0.32
▸ PRKAG1 P54619 1/20 0.32
▸ PRKAA2 P54646 1/20 0.32
▸ PRKAA1 Q13131 1/20 0.32
▸ PRKAG3 Q9UGI9 1/20 0.32
▸ PRKAG2 Q9UGJ0 1/20 0.32
▸ PRKAB1 Q9Y478 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19709379 1.00 HRH3 (0.43) HRH3EHMT2HRH2HRH1MAOB
SCHEMBL19709043 1.00 HRH3 (0.43) HRH3EHMT2HRH2HRH1MAOB
SCHEMBL12865863 0.89 KCNH2 (0.39) HRH3EHMT2
SCHEMBL22924094 0.89 KCNH2 (0.39) HRH3EHMT2
SCHEMBL24702321 0.89 KCNH2 (0.39) HRH3EHMT2
SCHEMBL22509435 0.87 HRH3 (0.41) HRH3EHMT2HRH2HRH1MAOB
SCHEMBL23642066 0.87 HRH3 (0.41) HRH3EHMT2HRH2HRH1MAOB
SCHEMBL10025525 0.85 HRH2 (0.49) HRH3HRH2HRH1MAOB
SCHEMBL10025514 0.85 HRH2 (0.49) HRH3HRH2HRH1MAOB
SCHEMBL19700573 0.83 HRH3 (0.45) HRH3HRH2HRH1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364086-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS Epizyme, Inc. 2023-11-16 — — US disclosed
US-11672800-B2 Combination therapies with EHMT2 inhibitors Epizyme, Inc. (US) 2023-06-13 — — US disclosed
US-20210213014-A1 METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES Epizyme, Inc. 2021-07-15 — — US disclosed
US-20200113901-A1 METHODS OF USING EHMT2 INHIBITORS Epizyme, Inc. 2020-04-16 — — US disclosed
US-20200054635-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS Epizyme, Inc. 2020-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364086-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS EHMT2, BHMT, SHMT2 HRH3 2154/4885EHMT2 1/4885HRH2 2900/4885
US-20200054635-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS EHMT2, BHMT, SHMT2 HRH3 2154/4885EHMT2 1/4885HRH2 2900/4885
US-20200113901-A1 METHODS OF USING EHMT2 INHIBITORS EHMT2, EHMT1, BHMT HRH3 1486/4885EHMT2 1/4885HRH2 2984/4885
US-11672800-B2 Combination therapies with EHMT2 inhibitors EHMT2, BHMT, SHMT2 HRH3 2154/4885EHMT2 1/4885HRH2 2900/4885
US-20210213014-A1 METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES EHMT2, BHMT2, BHMT HRH3 315/4885EHMT2 1/4885HRH2 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.